FOLD News and Press, Amicus Therapeutics Inc. From 11/11/19

Carbonite (NASDAQ: CARB ) +25%  on being acquired for $1.42B. More news on: Carbonite, Inc., Qurate Retail, Inc., Assembly Biosciences, Inc., Stocks on the move, Read more ...

Amicus Therapeutics ( FOLD ) Q3 results : Revenues: $48.8M (+136.9%). More news on: Amicus Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

Amicus Therapeutics (NASDAQ: FOLD ): Q3 GAAP EPS of -$0.24 beats by $0.08 . More news on: Amicus Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

            3Q19 Galafold ® (migalastat) Revenue of $48.8M   and 1,000+ Patients on Therapy Reflects Continued Strong Global Uptake Reiterating Upwardly Revised FY19 Revenue Guidance of $170M-$180M Comp...

Amicus Therapeutics (NASDAQ: FOLD ) is scheduled to announce Q3 earnings results on Monday, November 11th, before market open. The consensus EPS Estimate is -$0.32 (+61.9% Y/Y) and the consensus Revenue Estimate is $48.05M (+133.3% Y/Y). Over the last 2 years, FOLD has beaten EPS esti...

There seems no respite for the global markets from uncertainties of the U.S. - China trade war. Although both countries claim progress in the first phase of the deal, talks are far from over. Then, we have increased political uncertainty ahead of the fiscal 2020 presidential elections. The Bre...

CRANBURY, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 11, 2019 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2019. ...

New Data Support Meaningful Impact on Motor and Language Function in Children with Fatal Neurologic Disease Evidence of Disease Stabilization in 7 of 8 Children with Data for up to 2 Years Post-Treatment CRANBURY, N.J., and CHARLOTTE, N.C., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Ami...

Shares of rare-disease specialist Amicus Therapeutics (NASDAQ: FOLD) have been tumbling for several months over competitive concerns for its lead drug candidate. While the first-mover advantage tends to be overblown in most investing discussions, that's typically not the case when it comes...

On the good news front in today's series, Stealth BioTherapeutics ( MITO ) and Alexion Pharmaceuticals ( ALXN ) have agreed to co-develop and commercialize elamipretide for mitochondrial diseases. Elamipretide, an inner mitochondrial membrane-targeting therapeutic, is Stealth BioTherapeutics...